Senti Biosciences (SNTI) Income from Continuing Operations (2021 - 2025)
Senti Biosciences' quarterly Income from Continuing Operations came in at 18539000.0 in Q4 2025, down 16.33% year-on-year from 22156433.67 in Q4 2024, and down 10.47% quarter-over-quarter from 16782000.0 in Q3 2025.
Senti Biosciences has reported Income from Continuing Operations for 5 years, with the latest figure at 18539000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations fell 16.33% year-over-year to 18539000.0; the trailing twelve-month figure through Dec 2025 stood at 67852000.0 (down 12.91% YoY), and the FY2025 full-year result was 67852000.0, down 12.92% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 18539000.0, down from 16782000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1178.0 in Q1 2021, with the low at 43293000.0 in Q3 2023.
- Average Income from Continuing Operations over 5 years is 15272313.3, with a median of 15365500.0 recorded in 2022.
- Year-over-year, Income from Continuing Operations slumped 997692.87% in 2022 and jumped 65.2% in 2024.
- Tracing SNTI's Income from Continuing Operations over 5 years: stood at 3857088.0 in 2021, then sank by 306.16% to 15666000.0 in 2022, then slipped by 16.63% to 18272000.0 in 2023, then advanced by 12.78% to 15937000.0 in 2024, then dropped by 16.33% to 18539000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 18539000.0 (Q4 2025), 16782000.0 (Q3 2025), and 16528000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -18.54 Mn |
| Sep 30, 2025 | -16.78 Mn |
| Jun 30, 2025 | -16.53 Mn |
| Mar 31, 2025 | -16.00 Mn |
| Dec 31, 2024 | -15.94 Mn |
| Sep 30, 2024 | -15.07 Mn |
| Jun 30, 2024 | -13.12 Mn |
| Mar 31, 2024 | -15.97 Mn |
| Dec 31, 2023 | -18.27 Mn |
| Sep 30, 2023 | -43.29 Mn |
| Jun 30, 2023 | -14.39 Mn |
| Mar 31, 2023 | -13.90 Mn |
| Dec 31, 2022 | -15.67 Mn |
| Sep 30, 2022 | -14.21 Mn |
| Jun 30, 2022 | -21.74 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -3.86 Mn |
| Sep 30, 2021 | -11.42 Mn |
| Jun 30, 2021 | -8.99 Mn |
| Mar 31, 2021 | -1,178.00 |